GlaxoSmithKline Pharma Share Price

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.As of 15 Jun 2026, GlaxoSmithKline Pharma share price is ₹2,121.50. The stock opened at ₹2,116.00, compared to its previous close of ₹2,103.20. During today's trading session, GlaxoSmithKline Pharma share price moved in the range of ₹2,088.10 to ₹2,131.90, with an average price of ₹2,110.00 for the day. Looking at its last 52-week, the stock has touched a low of ₹2,088.10 and a high of ₹2,131.90. On the performance front, GlaxoSmithKline Pharma share price has declined by 18.43% over the last six months and is down 36.10% on a year-on-year basis.

The market capitalization of GlaxoSmithKline Pharma is ₹35,926 Crs, with a P/E ratio of 37.3 and a dividend yield of 2.50%.